Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MD Published 2022-01-21 Download video MP4 360p Recommendations 31:25 Multiple Myeloma 101: Diagnosis, Prognosis, and Risk: Nikhil C. Munshi, MD 54:28 David Sinclair on the Brink of Anti-Aging: Reprogramming Cells for Eternal Youth 1:10:32 Newly Diagnosed Multiple Myeloma | Diagnosis, Initial Treatment | ASCT, Maintenance Therapy, Goals 51:07 Sophie's SEVERE Chronic Fatigue Syndrome Recovery Story! 23:40 Fighting Colorectal Cancer With Diet and Exercise | Dana-Farber Cancer Institute 1:32:16 An Answer to Cancer? Using the immune system to fight cancer -- Longwood Seminar 1:34:05 The Great Partisan Shift | Robert F. Kennedy Jr. | EP 484 38:36 Atrial Fibrillation: New Solutions for an Old Problem 16:43 ASH 2023 Multiple Myeloma Highlights – PERSEUS, IsKia, Bortezomib dosing, KarMMA-3 54:22 Dr. Thomas Seyfried: Cancer as a Mitochondrial Metabolic Disease 35:14 Unlocking the Potential of Methylene Blue 55:12 Celiac Disease: 2021 Update 33:11 Brain Cancer and Immunotherapy with Dr. David Reardon 1:30:56 The Exercise Neuroscientist: NEW RESEARCH, The Shocking Link Between Exercise And Dementia! 54:01 Aspirin and cancer: the emerging evidence 13:50 4 Tricks for when doctors gaslight you - Dr. Kaveh LIVE 1:23:46 MD vs. Machine: Artificial intelligence in health care Similar videos 44:05 What are new treatment options for newly-diagnosed multiple myeloma patients? Dr. Paul G. Richardson 47:06 Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-Farber 47:17 New Directions in Treating Multiple Myeloma in the Era of Novel Agents 35:50 Dr. Paul Richardson on novel approaches for treating multiple myeloma | Dana-Farber Cancer Institute 08:06 Mezigdomide (CC-92480) | Paul Richardson, MD | ASH 2022 10:16 Melflufen: current trials and future directions 24:20 Future of Novel Next Generation Therapy in the Management of Relapsed/Refractory Multiple Myeloma 57:14 Multiple Myeloma Symposium: Future of Treatment | Dana-Farber Cancer Institute 44:44 2019 Multiple Myeloma Symposium | Novel and Next Generation Therapy 17:24 Dr. Paul G. Richardson Provides Study Updates on the Phase 3 DETERMINATION Trial for NDMM patients 46:00 Current and Future Treatment of Multiple Myeloma 37:45 Multiple Myeloma: Novel Agents | Dana-Farber Cancer Institute 1:28:28 mPatient Myeloma Radio: Dr. Paul Richardson, MD, Dana-Farber Cancer Institute 03:42 IMW 2019: the promising introduction of new treatment strategies 1:01:20 Myeloma Crowd Radio: Paul Richardson, MD, Dana Farber Cancer Institute 10:44 Isatuximab Plus Pomalidomide/Low-Dose Dex Vs Pomalidomide/Low-Dose Dex in Pts with RRMM (ICARIA-MM) 02:32 Paul G. Richardson, MD, considers progression-free survival in MM when treating with isatuximab 11:06 First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dex in pts with RRMM 20:53 Novel small molecules in multiple myeloma: Update on key results from emerging clinical studies More results